- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Ongoing
Phase
I/II
Principal Investigator(s)
John Steytler
Objective
A Randomized, Double-Blind, Phase 1b Study in Healthy HIV-Negative Women to Evaluate the Pharmacokinetics, Safety, and Bleeding Patterns Associated With 90-Day Use of Core-Sheath Vaginal Rings Releasing Dapivirine and Levonorgestrel
Last updated September 23, 2022
Prevention Option(s)
Multipurpose Prevention Technologies
PrEP
Study Design
Randomized
Double-blind
Arms and Assigned Interventions
Description
Arm Intervention/treatment
Experimental: IPM Ring-105
Ring-105 (xx mg dapivirine + xxx mg levonorgestrel)
Mode of Delivery
Ring
Products
Dapivirine-Levonorgestrel ring
ARMs
Experimental
Description
Active Comparator: IPM Ring-106.
Ring-106 (xx mg dapivirine + xxx mg levonorgestrel)
Mode of Delivery
Ring
Products
Dapivirine-Levonorgestrel ring
ARMs
Active Comparator
Official Code
Trial Sponsors
IPM, NICHD, NIH
June 2022
September 2023
Enrollment
40
18
Years
45
Days
Population
Women
Sites
Oregon Health & Science University
Portland, Oregon
United States of America
Magee Women's Hospital of UPMC
Pittsburgh
United States of America